Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1997-04-03
1998-12-08
Robinson, Douglas
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
536 181, A61K 3170
Patent
active
058469443
ABSTRACT:
The compound secoisolariciresinal diglucoside (SDG), obtained from flaxseed is used for reducing or preventing the development of hypercholesterolemic atherosclerosis and for reducing total cholesterol in humans or animals. It is also used for treating diabetes mellitus.
REFERENCES:
patent: 5340742 (1994-08-01), Barclay
patent: 5518918 (1996-05-01), Barclay
Bakke, JE and Klosterman, HJ: "A New Diglucoside From Flaxseed" Proc. North Dakota Acad. Sci. 10, 18-22, 1956.
Klosterman, HJ and Smith, F: "The Isolation of .beta.-Hydroxy-.beta.-Methylglutaric Acid From the Seed of Flax", J. Am. Chem. Soc. 76, 1229-1230, (Mar. 5, 1954).
MacRae, WD and Towers, GHN: "Biological Activities of Lignans", Phytochemistry, vol. 23, No. 6, pp. 1207-1220, 1984.
Harris, RK and Haggerty, WJ: "Assays for Potentially Anticarcinogenic Phytochemicals in Flaxseed", Cereal Foods World, vol. 38, No. 3, pp. 147-151, (Mar. 1993).
Bambagiotti-Alberti, M et al.,: "Revealing the Mammalian Lignan Precursor Secoisolariciresinol Diglucoside in Flax Seed by Ionspray Mass Spectometry", Rapid Communications in Mass Spectometry, vol. 8, pp. 595-598, 1994.
Obermeyer, WR et al.,: "Chemical Studies of Phytoestrogens in Flas and Chaparral", Society for Experimental Biology and Medicine, pp. 6-12, 1995.
Ratnayake et al., "Chemical and Nutritional Studies of Flaxseed (Variety Linott) in Rats," J. Nutritional Biochemistry, 3, 232-240 (May 1992).
Thompson et al., "Flaxseed and Its Lignan and Oil Components Reduce Mammary Tumor Growth at a Late Stage of Carcinogenesis," Carcinogenesis, 17(6), 1371-1376 (1996).
Clark et al., "Omega-3 Fatty Acid Supplementation in Clinical and Experimental Lupus Nephritis," part of Proceedings From The National Kidney Foundation Annual Meeting--Symposium on Essential Fatty Acid Deficiencies and .omega.-3 Unsaturated Fat Dietary Supplementation in Glomerulonephritis: Basis and Practice Baltimore, Md, Nov. 11-15, 1992; American J. of Kidney Diseases, 23(5), 644-647 (May 1994).
Kelley et al., "Dietary .alpha.-Linolenic Acid Alters Tissue Fatty Acid Composition, But Not Blood Lipids, Lipoproteins or Coagulation Status in Humans," Lipids, 28(6), 533-538 (Jun. 1993).
Bierenbaum et al., "Reduced Atherogenic Risk in Hyperlipemic Humans with Flax Seed Supplementation: A Preliminary Report," J. Amer. College of Nutrition, 12(5), 501-504 (Oct. 1993).
Cunnane et al., "High .alpha.-Linolenic Acid Flaxseed (Linum usitatissimum): Some Nutritional Properties in Humans," British J. of Nutrition, 69, 443-453 (1993).
Ranhotra et al., "Lipidemic Response in Rats Fed Flaxseed Oil and Meal," Cereal Chemistry, 70(3), 364-366 (1993).
Jenab et al., "The Influence of Flaxseed and Lignans on Colon Carcinogenesis and .beta.-Glucuronidase Activity," Carcinogenesis, 17(6), 1343-1348 (1996).
Bambagiotti-Albert et al., "Investigation of Mammalian Lignan Precursors in Flax Seed: First Evidence of Secoisolariciresinol Diglucoside in Two Isomeric Forms by Liquid Chromatography/Mass Spectrometry," Rapid Comm. Mass Spectrometry, 8(12), 929-932 (1994).
Crane I. Eric
Robinson Douglas
The University of Saskatchewan
LandOfFree
Purified SDG as an antioxidant does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Purified SDG as an antioxidant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Purified SDG as an antioxidant will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-177337